Findings

What do systematic reviews say?

1,139 questions · 1,173 findings · 89 reviews · Neuromuscular

Sort:Best matchNewestHighest certainty Download CSV

No studies found 302 · 25.7%GRADE not reported 119 · 10.1%Very low 267 · 22.8%Low 239 · 20.4%Moderate 177 · 15.1%High 69 · 5.9%

Intervention not reported

Maximum voluntary contraction in glycogen storage disease type V % · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
High

Intervention not reported

Impairment of activities of daily living (ADL) in glycogen storage disease type V Visual numeric scale. Scale from: 1 to 10. · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
High

Intervention not reported

Adverse events in mitochondrial diseases · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 38 participants
GRADE not reported

Intervention not reported

ALS Functional Rating Scale (ALSFRS) score at 3 months Scale from: 0 to 40 (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 43 participants
Low

Intervention not reported

Short‐Form‐36 Health Survey (SF‐36) score at 3 months Scale from: 0 to 100 (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Moderate

Intervention not reported

Fatigue Severity Scale score at 3 months Scale from: 0 to 63 (lower is better). · people with amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 43 participants
Low

Intervention not reported

Manual Muscle Testing score at 3 months Right and left shoulder abduction, elbow flexion and extension, finger abduction and extension, hip flexion, knee flexion and extension, foot dorsiflexion and plantarflexion assessed and graded 0 to 5 Medica... · people with amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Moderate

Intervention not reported

Upper extremity maximum voluntary isometric contraction score at 3 months Quantitative Muscle Assessment (QMA) system. Data were normalized, summed and averaged to yield an U/E megascore (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Moderate

Intervention not reported

Lower extremity maximum voluntary isometric contraction score at 3 months Quantitative Muscle Assessment (QMA) system. Data were normalized, summed and averaged to yield a L/E megascore (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Moderate

Intervention not reported

Adverse effects related to the intervention · people with amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 43 participants
GRADE not reported

Topiramate 200 to 400 mg vs placebo

Participant‐reported pain relief of 50% or greater · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)

1 finding from 1 review

Topiramate for neuropathic pain and fibromyalgia in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 317 participants
GRADE not reported

Topiramate 200 to 400 mg vs placebo

Participant‐reported pain relief of 30% or greater · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)

1 finding from 1 review

Topiramate for neuropathic pain and fibromyalgia in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 317 participants
GRADE not reported

Topiramate 200 to 400 mg vs placebo

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)

The review found no eligible studies for this question.

1 finding from 1 review

Topiramate for neuropathic pain and fibromyalgia in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topiramate 200 to 400 mg vs placebo

Patient Global Impression of Change much or very much improved · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)

1 finding from 1 review

Topiramate for neuropathic pain and fibromyalgia in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 399 participants
GRADE not reported

Topiramate 200 to 400 mg vs placebo

Withdrawals due to adverse events · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)

Topiramate 200 to 400 mg probably leads to higher adverse event withdrawals compared with placebo (moderate certainty).

1 finding from 1 review

Topiramate for neuropathic pain and fibromyalgia in adults 2013 · Cochrane Headline outcomes only
RR 3.4 [4.3, 7.1]
1038 participants
Moderate

Topiramate 200 to 400 mg vs placebo

Serious adverse events · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)

Topiramate 200 to 400 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Topiramate for neuropathic pain and fibromyalgia in adults 2013 · Cochrane Headline outcomes only
RR 0.9 [0.6, 1.3]
1586 participants
Moderate

Topiramate 200 to 400 mg vs placebo

Death · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)

The review found no eligible studies for this question.

1 finding from 1 review

Topiramate for neuropathic pain and fibromyalgia in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Repetitive transcranial magnetic stimulation (rTMS) vs sham rTMS

Changes to the ALSFRS‐R scores at 12 months · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Low

Repetitive transcranial magnetic stimulation (rTMS) vs sham rTMS

Muscle strength · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Low

Repetitive transcranial magnetic stimulation (rTMS) vs sham rTMS

Changes to FSS at 12 months · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease 2013 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported